Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)
NCT01213095
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Lymphoma
Interventions
DRUG:
rituximab
Sponsor
Dong-A University Hospital